ATE448247T1 - Fusionspolypeptide vom glp-1 (glucagon-like peptide-1) mit erhöhten peptidaseresistenz - Google Patents

Fusionspolypeptide vom glp-1 (glucagon-like peptide-1) mit erhöhten peptidaseresistenz

Info

Publication number: ATE448247T1
Authority: AT; Austria
Prior art keywords: glp; peptide; component; sequence; glucagon
Prior art date: 2005-09-22

Application number

AT05020718T

Other languages

English (en)

Inventor

Peter Geigle

Christine Wallrapp

Eric Thoenes

Original Assignee

Biocompatibles Uk Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-22

Filing date

2005-09-22

Publication date

2009-11-15

2005-09-22 Application filed by Biocompatibles Uk Ltd filed Critical Biocompatibles Uk Ltd

2009-11-15 Application granted granted Critical

2009-11-15 Publication of ATE448247T1 publication Critical patent/ATE448247T1/de

Links

108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
102400000322 Glucagon-like peptide 1 Human genes 0.000 title abstract 6
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 6
230000004927 fusion Effects 0.000 title abstract 4
102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
101800000224 Glucagon-like peptide 1 Proteins 0.000 title 2
229920001184 polypeptide Polymers 0.000 title 1
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 abstract 1
101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 abstract 1
102400000326 Glucagon-like peptide 2 Human genes 0.000 abstract 1
101800000221 Glucagon-like peptide 2 Proteins 0.000 abstract 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
208000034615 apoptosis-related disease Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
208000015122 neurodegenerative disease Diseases 0.000 abstract 1
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- G—PHYSICS
- G07—CHECKING-DEVICES
- G07F—COIN-FREED OR LIKE APPARATUS
- G07F11/00—Coin-freed apparatus for dispensing, or the like, discrete articles
- G07F11/02—Coin-freed apparatus for dispensing, or the like, discrete articles from non-movable magazines
- G07F11/04—Coin-freed apparatus for dispensing, or the like, discrete articles from non-movable magazines in which magazines the articles are stored one vertically above the other
- G07F11/16—Delivery means
- G07F11/165—Delivery means using xyz-picker or multi-dimensional article picking arrangements

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Biochemistry (AREA)
Endocrinology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Toxicology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Obesity (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
General Physics & Mathematics (AREA)
Physics & Mathematics (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

AT05020718T 2005-09-22 2005-09-22 Fusionspolypeptide vom glp-1 (glucagon-like peptide-1) mit erhöhten peptidaseresistenz ATE448247T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP05020718A EP1767545B1 (de)	2005-09-22	2005-09-22	Fusionspolypeptide vom glp-1 (glucagon-like peptide-1) mit erhöhten peptidaseresistenz

Publications (1)

Publication Number	Publication Date
ATE448247T1 true ATE448247T1 (de)	2009-11-15

Family

ID=35700191

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05020718T ATE448247T1 (de)	2005-09-22	2005-09-22	Fusionspolypeptide vom glp-1 (glucagon-like peptide-1) mit erhöhten peptidaseresistenz

Country Status (24)

Country	Link
US (2)	US8431533B2 (de)
EP (5)	EP1767545B1 (de)
JP (2)	JP5222729B2 (de)
KR (1)	KR20080064840A (de)
CN (1)	CN101273058A (de)
AT (1)	ATE448247T1 (de)
AU (1)	AU2006299134B2 (de)
BR (1)	BRPI0616107A2 (de)
CA (1)	CA2619053A1 (de)
CY (1)	CY1109778T1 (de)
DE (1)	DE602005017628D1 (de)
DK (1)	DK1767545T3 (de)
EA (1)	EA013796B1 (de)
ES (3)	ES2336575T3 (de)
HK (1)	HK1129121A1 (de)
HR (1)	HRP20100062T1 (de)
IL (1)	IL188904A0 (de)
PL (1)	PL1767545T3 (de)
PT (1)	PT1767545E (de)
RS (1)	RS51319B (de)
SG (1)	SG165414A1 (de)
SI (1)	SI1767545T1 (de)
WO (1)	WO2007039140A1 (de)
ZA (1)	ZA200803488B (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE448247T1 (de)	2005-09-22	2009-11-15	Biocompatibles Uk Ltd	Fusionspolypeptide vom glp-1 (glucagon-like peptide-1) mit erhöhten peptidaseresistenz
JP2009513627A (ja) *	2005-10-27	2009-04-02	ペプトロンカンパニーリミテッド	生理活性物質−血液蛋白質複合体及びこれを利用する生理活性物質の安定化方法
US20130172274A1 (en)	2005-12-20	2013-07-04	Duke University	Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en)	2005-12-20	2014-09-23	Duke University	Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
ATE444741T1 (de) *	2006-05-10	2009-10-15	Biocompatibles Uk Ltd	Glp-1 peptide enthaltende kugelförmige mikrokapseln, deren produktion und deren verwendung
EP1972349A1 (de) *	2007-03-21	2008-09-24	Biocompatibles UK Limited	Mit Polymer(en) konjugierte GLP-1-Fusionspeptide, ihre Herstellung und Verwendung
EP1975176A1 (de) *	2007-03-27	2008-10-01	Biocompatibles UK Limited	Neue GLP-1-Fusionspeptide, ihre Herstellung und Verwendung
WO2009158704A2 (en)	2008-06-27	2009-12-30	Duke University	Therapeutic agents comprising elastin-like peptides
EP2163243A1 (de) *	2008-09-12	2010-03-17	Biocompatibles UK Limited	Behandlung akuter Herzinfarkte mithilfe eingekapselter Zellen, welche GLP-1-Peptide oder deren Analoga kodieren und absondern
CN101993485B (zh)	2009-08-20	2013-04-17	重庆富进生物医药有限公司	促胰岛素分泌肽类似物同源二聚体及其用途
EP2533813B1 (de) *	2010-02-11	2016-06-01	F.Hoffmann-La Roche Ag	Proteinkonjugate für trypsinvermittelte Pegylierung durch Transamidierung und Methoden
EP2623512A4 (de) *	2010-10-01	2014-03-26	Mmt Co Ltd	Zur bindung von immunglobulin fähiges peptid
CN102766204B (zh) *	2011-05-05	2014-10-15	天津药物研究院	胰高血糖素样肽-1突变体多肽及其制备方法和其应用
CN102363633B (zh) *	2011-11-16	2013-11-20	天津拓飞生物科技有限公司	胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用
CN104918961A (zh)	2012-11-20	2015-09-16	梅德瑞斯糖尿病有限责任公司	用于胰岛素抗性的改良的肽药物
CN104371019B (zh) *	2013-08-13	2019-09-10	鸿运华宁（杭州）生物医药有限公司	一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
CN104707131A (zh) *	2013-12-13	2015-06-17	上海建华精细生物制品有限公司	一种药物组合物及其制备方法和用途
CN117582516A (zh)	2014-05-28	2024-02-23	梅德瑞斯糖尿病有限责任公司	针对胰岛素抵抗的改良肽药物
EP3257524B1 (de)	2015-02-11	2020-08-26	Gmax Biopharm LLC	Stabilisiertes lösungspräparat eines pharmazeutischen glp-1r-antikörperfusionsproteins
EP3393496B1 (de)	2015-12-23	2023-10-11	The Johns Hopkins University	Langwirkender glp-1r-agonist als therapie neurologischer und neurodegenerativer erkrankungen
CN107818433B (zh) *	2016-09-14	2022-07-05	菜鸟智能物流控股有限公司	取件方法、物流信息处理方法及装置、系统
WO2018104559A1 (en) *	2016-12-09	2018-06-14	Zealand Pharma A/S	Glp-1/glp-2 dual agonists
CN110088125B (zh) *	2016-12-09	2023-10-03	西兰制药公司	酰化的glp-1/glp-2双重激动剂
WO2018104558A1 (en) *	2016-12-09	2018-06-14	Zealand Pharma A/S	Acylated glp-1/glp-2 dual agonists
CN108341880B (zh) *	2017-01-23	2023-07-04	天津药物研究院有限公司	含有胰高血糖素样肽-1和胰高血糖素的片段类似物的嵌合多肽及其用途
KR101827245B1 (ko) *	2017-12-26	2018-02-08	(주)제이유타이드	알라린을 주성분으로 하는 요독증 치료제
US11541028B2 (en)	2018-01-03	2023-01-03	Altimmune Inc.	Peptide pharmaceuticals for treatment of NASH and other disorders
KR101903564B1 (ko) *	2018-01-31	2018-11-13	한국지질자원연구원	제지공정에서 발생되는 부산물의 재활용 방법
SI3774862T1 (sl)	2018-04-05	2022-10-28	Sun Pharmaceutical Industries Limited	Novi analogi GLP-1
AU2019410643A1 (en)	2018-12-21	2021-08-12	Jiangsu Hengrui Medicine Co., Ltd.	Bispecific protein
WO2021182928A1 (ko) *	2020-03-12	2021-09-16	주식회사 에스엘메타젠	신규 이중 특이성 단백질 및 그의 용도
KR102349717B1 (ko) *	2020-03-12	2022-01-11	주식회사 에스엘메타젠	신규 대사증후군 및 그와 관련된 질환 치료용 약학 조성물
KR20220008788A (ko) *	2020-07-14	2022-01-21	(주)지아이이노베이션	글루카곤-유사 펩타이드-1 및 글루카곤-유사 펩타이드-2를 포함하는 융합 단백질 및 이의 용도
CA3200351A1 (en) *	2020-11-27	2022-06-02	Ok Cheol Jeon	Oral formulation of biologically active material conjugate having biotin moiety, fatty acid moiety, or combination thereof coupled thereto
GB2617717A (en) *	2020-11-27	2023-10-18	D&D Pharmatech Inc	Biologically active material conjugate having biotin moiety, fatty acid moiety, or combination thereof coupled thereto
CN112661862B (zh) *	2020-12-25	2023-03-31	深圳大学	一种融合蛋白及其制备方法和应用
CN113846124A (zh) *	2021-09-26	2021-12-28	康霖生物科技（杭州）有限公司	一种用于糖代谢相关疾病基因治疗的核酸构建体
US12171806B2 (en)	2021-09-28	2024-12-24	Spitfire Pharma Llc	Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balanced agonists
CN114621339B (zh) *	2021-12-28	2022-09-23	北京惠之衡生物科技有限公司	一种长效glp-1衍生物
CN115920004A (zh) *	2022-11-11	2023-04-07	深圳市图微安创科技开发有限公司	药物组合物及其制备方法
WO2024144431A1 (ru) *	2022-12-29	2024-07-04	Авва Фармасьютикалс Лтд	Новый штамм-продуцент escherichia coli, продуцирующий гибридный белок cbd-hs-es-glp1, и способ получения полипептида glp-1
WO2025005743A1 (ko) *	2023-06-30	2025-01-02	주식회사 휴온스랩	Glp 유사체를 유효성분으로 포함하는 비만 예방 또는 치료용 약학적 조성물

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US586128A (en) *		1897-07-13		Toilet-paper holder
US4352883A (en) *	1979-03-28	1982-10-05	Damon Corporation	Encapsulation of biological material
EP0018435B1 (de)	1979-10-16	1984-03-07	Winfried Dr. med. Stöcker	Vorrichtung zur Durchführung von Mikroanalysen
US4596792A (en)	1981-09-04	1986-06-24	The Regents Of The University Of California	Safe vaccine for hepatitis containing polymerized serum albumin
JPS5938877A (ja)	1982-08-30	1984-03-02	Musashi Eng Kk	紙葉判別方法
US4588585A (en)	1982-10-19	1986-05-13	Cetus Corporation	Human recombinant cysteine depleted interferon-β muteins
US4737462A (en)	1982-10-19	1988-04-12	Cetus Corporation	Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en)	1983-04-15	1985-05-21	Cetus Corporation	Human recombinant interleukin-2 muteins
DD224119A1 (de)	1983-11-07	1985-06-26	Univ Schiller Jena	Temperierbarer probentraeger
US4599230A (en)	1984-03-09	1986-07-08	Scripps Clinic And Research Foundation	Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en)	1984-03-09	1986-07-08	Scripps Clinic And Research Foundation	Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4959314A (en)	1984-11-09	1990-09-25	Cetus Corporation	Cysteine-depleted muteins of biologically active proteins
US4608251A (en)	1984-11-09	1986-08-26	Pitman-Moore, Inc.	LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US5116943A (en)	1985-01-18	1992-05-26	Cetus Corporation	Oxidation-resistant muteins of Il-2 and other protein
US4601903A (en)	1985-05-01	1986-07-22	The United States Of America As Represented By The Department Of Health And Human Services	Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US5144139A (en)	1985-08-05	1992-09-01	Biotrack, Inc.	Capillary flow device
US4687529A (en)	1985-08-30	1987-08-18	Miles Laboratories, Inc.	Method of making a reagent test device containing hydrophobic barriers
CA1292176C (en)	1985-09-18	1991-11-19	Joel M. Blatt	Volume metering capillary gap device for applying a liquid sample onto a reactive surface
US5017691A (en)	1986-07-03	1991-05-21	Schering Corporation	Mammalian interleukin-4
US6849708B1 (en)	1986-05-05	2005-02-01	The General Hospital Corporation	Insulinotropic hormone and uses thereof
US4965195A (en)	1987-10-26	1990-10-23	Immunex Corp.	Interleukin-7
US4904584A (en)	1987-12-23	1990-02-27	Genetics Institute, Inc.	Site-specific homogeneous modification of polypeptides
JP3262329B2 (ja)	1990-01-24	2002-03-04	アイ．バックレイ，ダグラス	糖尿病治療に有用なｇｌｐ―１アナログ
DE69210645T2 (de) *	1991-02-19	1996-11-28	Takeda Chemical Industries, Ltd., Osaka	Verfahren zur Herstellung von cysteinfreien Peptiden
CA2062338A1 (en)	1991-03-15	1992-09-16	Zia Yassinzadeh	Electronic control cartridge and method of simulating light transmission patterns
GB9311147D0 (en)	1993-05-28	1993-07-14	Long Ashton Research Station	Regulation of plant growth
US5705483A (en)	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
US5512549A (en)	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
BE1008987A3 (fr)	1995-01-06	1996-10-01	Robyn Pierre	Blocs refractaires a canalisations pour sols de fours verriers et installation dans les sols de circuits de refroidissement ou de chauffage, permettant d'ameliorer le controle thermique des sols et la qualite du verre.
JP3643863B2 (ja)	1995-08-09	2005-04-27	アークレイ株式会社	液体保持具とその製造方法
WO1997031943A1 (en)	1996-03-01	1997-09-04	Novo Nordisk A/S	Use of a pharmaceutical composition comprising an appetite-suppressing peptide
US6165739A (en)	1996-03-13	2000-12-26	Compucyte Corporation	Multiple simultaneous testing media
ATE493998T1 (de)	1996-08-08	2011-01-15	Amylin Pharmaceuticals Inc	Pharmazeutische zusammensetzung mit einem exendin-4-peptid
RU2214419C2 (ru)	1996-08-30	2003-10-20	Ново Нордиск А/С	Glp-1 производные
WO1998020895A1 (en)	1996-11-12	1998-05-22	Novo Nordisk A/S	Use of glp-1 peptides
EP1045898A2 (de)	1998-01-12	2000-10-25	Betagene, Inc.	Zusammensetzungen und verfahren für die regulierung der expression aus neuroendocrinezellinien
WO1999044508A1 (en)	1998-03-06	1999-09-10	Spectrx, Inc.	Integrated poration, harvesting and analysis device, and method therefor
EP1062229A1 (de) *	1998-03-09	2000-12-27	Zealand Pharmaceuticals A/S	Pharmakologisch aktive peptid-konjugate mit verringerter neigung enzymatisch hydrolysiert zu werden
AU3047299A (en)	1998-04-13	1999-11-01	Modex Therapeutiques, S.A.	Methods of delivering glp-1
US7259136B2 (en)	1999-04-30	2007-08-21	Amylin Pharmaceuticals, Inc.	Compositions and methods for treating peripheral vascular disease
US6267954B1 (en)	1999-11-24	2001-07-31	Universite De Paris V Rene-Descartes	Intraocular transplantation of encapsulated cells
US6706159B2 (en)	2000-03-02	2004-03-16	Diabetes Diagnostics	Combined lancet and electrochemical analyte-testing apparatus
ES2253353T3 (es)	2000-03-08	2006-06-01	Novo Nordisk A/S	Reduccion del colesterol serico.
DE10039643A1 (de) *	2000-08-14	2002-02-28	Max Planck Gesellschaft	Funktionalisierte Perylentetracarbonsäurediimide
ATE406384T1 (de) *	2000-12-07	2008-09-15	Lilly Co Eli	Glp-1 fusion proteine
AU2002255517A1 (en)	2001-02-09	2002-10-08	The University Of Illinois	Method and structure for microfluidic flow guiding
JP4689144B2 (ja)	2001-02-22	2011-05-25	ノバルティスアーゲー	眼球血管新生を処置するための方法
US20030034147A1 (en)	2001-05-31	2003-02-20	Houck Glenn M.	Apparatus which eliminates the need for idling by trucks
PT1412384E (pt)	2001-06-28	2008-03-28	Novo Nordisk As	Formulação estável de glp-1 modificado
CN1363654A (zh)	2001-07-19	2002-08-14	上海华谊生物技术有限公司	生产促胰岛素分泌肽glp－1(7－36)的基因工程菌以及生产glp－1(7－36)的方法
WO2003010305A1 (en)	2001-07-27	2003-02-06	Arhus Amt	Immortilized stem cells
US7576050B2 (en)	2001-07-31	2009-08-18	The United States Of America As Represented By The Department Of Health And Human Services	GLP-1 exendin-4 peptide analogs and uses thereof
US20040143104A1 (en)	2001-08-08	2004-07-22	Wadsworth Samuel C.	Methods of treating diabetes and other blood sugar disorders
JP2005508895A (ja)	2001-08-28	2005-04-07	イーライ・リリー・アンド・カンパニー	Ｇｌｐ−１および基礎インスリンの予備混合物
US7176278B2 (en)	2001-08-30	2007-02-13	Biorexis Technology, Inc.	Modified transferrin fusion proteins
US7166208B2 (en)	2004-03-03	2007-01-23	Stephen Eliot Zweig	Apoenzyme reactivation electrochemical detection method and assay
ATE352312T1 (de)	2001-12-29	2007-02-15	Novo Nordisk As	Kombinierte verwendung einer glp-1-verbindung und eines aldose reduktase inhibitors
AR038102A1 (es) *	2002-01-08	2004-12-29	Lilly Co Eli	Analogos extendidos de peptido 1 de tipo glucagon
GB2388898B (en)	2002-04-02	2005-10-05	Inverness Medical Ltd	Integrated sample testing meter
US20030191056A1 (en) *	2002-04-04	2003-10-09	Kenneth Walker	Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
US20030143113A2 (en)	2002-05-09	2003-07-31	Lifescan, Inc.	Physiological sample collection devices and methods of using the same
CA2497794A1 (en)	2002-09-06	2004-03-18	Bayer Pharmaceuticals Corporation	Modified glp-1 receptor agonists and their pharmacological methods of use
JP4548335B2 (ja) *	2003-03-07	2010-09-22	味の素株式会社	腸管細胞のインスリン産生細胞への変換誘導剤、及び糖尿病治療剤
US6969166B2 (en)	2003-05-29	2005-11-29	3M Innovative Properties Company	Method for modifying the surface of a substrate
US7057116B2 (en)	2003-06-02	2006-06-06	Intel Corporation	Selective reference plane bridge(s) on folded package
US7452966B2 (en) *	2003-06-12	2008-11-18	Eli Lilly And Company	GLP-1 analog fusion proteins
EP1498143A1 (de)	2003-07-18	2005-01-19	Aventis Pharma S.A.	Selbstemulgierende und selbstmicroemulgierende Formulierungen zur oralen Verabreichung von Taxoiden
WO2005014049A2 (en)	2003-08-08	2005-02-17	Novo Nordisk A/S	Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides
EP1677819A1 (de)	2003-10-10	2006-07-12	Novo Nordisk A/S	Moleküle mit langzeitwirkung in formulierungen mit verzögerter freisetzung
MXPA06006746A (es) *	2003-12-18	2006-08-18	Novo Nordisk As	Analogos de glp-1 novedosos ligados a agentes similares a albumina.
WO2005072216A2 (en)	2004-01-20	2005-08-11	The Curators Of The University Of Missouri	Supported molecular biofluid viscosity sensors for in vitro and in vivo use
KR20140011431A (ko)	2004-02-11	2014-01-28	아밀린 파마슈티칼스, 엘엘씨.	선택가능한 특성을 갖는 하이브리드 폴리펩티드
RU2376603C2 (ru)	2004-03-05	2009-12-20	Эгомедикаль Свисс Аг	Тест-система для определения концентрации анализируемого вещества в физиологической жидкости
WO2005097175A2 (en)	2004-03-31	2005-10-20	Centocor, Inc.	Human glp-1 mimetibodies, compositions, methods and uses
US20080300173A1 (en)	2004-07-13	2008-12-04	Defrees Shawn	Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
JP4637910B2 (ja)	2004-08-13	2011-02-23	エゴメディカルテクノロジーズアクチエンゲゼルシャフト	生理的又は水性の液体中の被分析物濃度を定量するための被分析物検査システム
US7442682B2 (en)	2004-10-19	2008-10-28	Nitto Denko Corporation	Transepithelial delivery of peptides with incretin hormone activities
KR20080050576A (ko)	2005-07-29	2008-06-09	앰프로틴 코포레이션	키메릭 치료제
ATE448247T1 (de)	2005-09-22	2009-11-15	Biocompatibles Uk Ltd	Fusionspolypeptide vom glp-1 (glucagon-like peptide-1) mit erhöhten peptidaseresistenz
ATE444741T1 (de)	2006-05-10	2009-10-15	Biocompatibles Uk Ltd	Glp-1 peptide enthaltende kugelförmige mikrokapseln, deren produktion und deren verwendung
EP1972349A1 (de)	2007-03-21	2008-09-24	Biocompatibles UK Limited	Mit Polymer(en) konjugierte GLP-1-Fusionspeptide, ihre Herstellung und Verwendung
EP1975176A1 (de)	2007-03-27	2008-10-01	Biocompatibles UK Limited	Neue GLP-1-Fusionspeptide, ihre Herstellung und Verwendung
EP2163243A1 (de)	2008-09-12	2010-03-17	Biocompatibles UK Limited	Behandlung akuter Herzinfarkte mithilfe eingekapselter Zellen, welche GLP-1-Peptide oder deren Analoga kodieren und absondern

2005
- 2005-09-22 AT AT05020718T patent/ATE448247T1/de active
- 2005-09-22 PL PL05020718T patent/PL1767545T3/pl unknown
- 2005-09-22 ES ES05020718T patent/ES2336575T3/es active Active
- 2005-09-22 DE DE602005017628T patent/DE602005017628D1/de active Active
- 2005-09-22 SI SI200530887T patent/SI1767545T1/sl unknown
- 2005-09-22 ES ES08021837T patent/ES2397289T3/es active Active
- 2005-09-22 EP EP05020718A patent/EP1767545B1/de active Active
- 2005-09-22 EP EP08021837A patent/EP2045265B1/de active Active
- 2005-09-22 PT PT05020718T patent/PT1767545E/pt unknown
- 2005-09-22 RS RSP-2010/0039A patent/RS51319B/sr unknown
- 2005-09-22 DK DK05020718.2T patent/DK1767545T3/da active
2006
- 2006-09-22 JP JP2008531616A patent/JP5222729B2/ja not_active Expired - Fee Related
- 2006-09-22 KR KR1020087009543A patent/KR20080064840A/ko not_active Application Discontinuation
- 2006-09-22 WO PCT/EP2006/009226 patent/WO2007039140A1/en active Application Filing
- 2006-09-22 EA EA200800699A patent/EA013796B1/ru not_active IP Right Cessation
- 2006-09-22 US US11/991,562 patent/US8431533B2/en not_active Expired - Fee Related
- 2006-09-22 EP EP06792228A patent/EP1926748B1/de not_active Not-in-force
- 2006-09-22 ZA ZA200803488A patent/ZA200803488B/xx unknown
- 2006-09-22 ES ES06792228T patent/ES2394218T3/es active Active
- 2006-09-22 CA CA002619053A patent/CA2619053A1/en not_active Abandoned
- 2006-09-22 EP EP09014513A patent/EP2174952A3/de not_active Withdrawn
- 2006-09-22 EP EP10009718A patent/EP2261245A1/de not_active Withdrawn
- 2006-09-22 AU AU2006299134A patent/AU2006299134B2/en not_active Ceased
- 2006-09-22 SG SG201006921-9A patent/SG165414A1/en unknown
- 2006-09-22 BR BRPI0616107-3A patent/BRPI0616107A2/pt not_active IP Right Cessation
- 2006-09-22 CN CNA2006800350367A patent/CN101273058A/zh active Pending
2008
- 2008-01-21 IL IL188904A patent/IL188904A0/en unknown
2009
- 2009-10-05 HK HK09109186.6A patent/HK1129121A1/xx not_active IP Right Cessation
2010
- 2010-02-02 HR HR20100062T patent/HRP20100062T1/hr unknown
- 2010-02-11 CY CY20101100139T patent/CY1109778T1/el unknown
2012
- 2012-05-29 US US13/482,354 patent/US8853159B2/en not_active Expired - Fee Related
2013
- 2013-01-25 JP JP2013012558A patent/JP2013099352A/ja active Pending

Also Published As

Publication number	Publication date
SI1767545T1 (sl)	2010-03-31
EP1767545A1 (de)	2007-03-28
JP5222729B2 (ja)	2013-06-26
WO2007039140A1 (en)	2007-04-12
US8853159B2 (en)	2014-10-07
CY1109778T1 (el)	2014-09-10
EP2045265A1 (de)	2009-04-08
CA2619053A1 (en)	2007-04-12
ES2397289T3 (es)	2013-03-06
BRPI0616107A2 (pt)	2011-06-07
EP1926748A1 (de)	2008-06-04
EP2174952A2 (de)	2010-04-14
JP2009508505A (ja)	2009-03-05
EP2174952A3 (de)	2010-11-17
KR20080064840A (ko)	2008-07-09
JP2013099352A (ja)	2013-05-23
US20120238497A1 (en)	2012-09-20
AU2006299134A1 (en)	2007-04-12
DE602005017628D1 (de)	2009-12-24
DK1767545T3 (da)	2010-03-15
EA200800699A1 (ru)	2008-10-30
CN101273058A (zh)	2008-09-24
SG165414A1 (en)	2010-10-28
ES2336575T3 (es)	2010-04-14
PT1767545E (pt)	2010-02-05
ES2394218T3 (es)	2013-01-23
EP1926748B1 (de)	2012-08-29
US8431533B2 (en)	2013-04-30
PL1767545T3 (pl)	2010-04-30
US20110130329A1 (en)	2011-06-02
RS51319B (sr)	2010-12-31
EA013796B1 (ru)	2010-06-30
HK1129121A1 (en)	2009-11-20
IL188904A0 (en)	2008-04-13
EP2045265B1 (de)	2012-11-21
EP1767545B1 (de)	2009-11-11
EP2261245A1 (de)	2010-12-15
AU2006299134B2 (en)	2012-02-23
ZA200803488B (en)	2009-10-28
HRP20100062T1 (hr)	2010-03-31

Publication	Publication Date	Title
ATE448247T1 (de)	2009-11-15	Fusionspolypeptide vom glp-1 (glucagon-like peptide-1) mit erhöhten peptidaseresistenz
WO2008116648A3 (en)	2008-12-31	Novel glp-1 fusion peptides, their production and use
JP5580784B2 (ja)	2014-08-27	選択可能な特性を有するハイブリッドポリペプチド
US20190085043A1 (en)	2019-03-21	Fusion proteins for treating a metabolic syndrome
JP2019085420A (ja)	2019-06-06	エラスチン様ペプチドを含む治療剤
Candeias et al.	2015	Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide
JP6121330B2 (ja)	2017-04-26	作用持続時間が増した改変ポリペプチド
EP2301962A3 (de)	2011-11-02	Erfindung betreffend GLP-1 und Exendin
WO2003033671A3 (en)	2005-12-29	Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
EP2390264A1 (de)	2011-11-30	GIP-Analog und Hybridpolypeptide mit auswählbaren Eigenschaften
WO2006127948A3 (en)	2007-04-19	N-terminally modified glp-1 receptor modulators
WO2007140284A3 (en)	2008-12-31	N-terminally modified glp-1 receptor modulators
WO2006017688A3 (en)	2006-08-03	Combination therapy using transferrin fusion proteins comprising glp-1
WO2006014287A8 (en)	2006-05-26	Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
JP2004509079A5 (de)	2005-08-18
US20110288001A1 (en)	2011-11-24	Biologically active proteins activatable by peptidase
CN101155828A (zh)	2008-04-02	Gip类似物和具有可选择性质的杂合多肽
JP6811190B2 (ja)	2021-01-13	プロテアーゼ耐性脂質付加ｇｌｐ−１類似体
Linderoth et al.	2021	GLP‐1 Receptor Agonists for the Treatment of Type 2 Diabetes and Obesity
Oskola et al.	2013	Angioprotektivnoe properties lowering drugs from the group of inhibitors of dipeptidyl peptidase-4
TH87281B (th)	2007-10-31	N-เทอร์มินัลลี มอดิไฟด์ glp-1 รีเซปเตอร์ มอดูเลเตอร์
TH87281A (th)	2007-10-31	N-เทอร์มินัลลี มอดิไฟด์ glp-1 รีเซปเตอร์ มอดูเลเตอร์

Legal Events

Date	Code	Title	Description
2010-05-15	UEP	Publication of translation of european patent specification	Ref document number: 1767545 Country of ref document: EP

Date

Code

Title

Description

2010-05-15

UEP

Publication of translation of european patent specification

Ref document number: 1767545

Country of ref document: EP